Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase...
Clinical Trial
Nicox Provides Third Quarter 2022 Financial and Business Highlights
Press Release Nicox Provides Third Quarter 2022 Financial and Business HighlightsTopline results of the NCX 470 Mont Blanc Phase 3...
H1 Unveils New Brand on the Heels of Significant Financial, Customer and Product Capabilities Growth
With a refined mission to connect the world with the right doctors, new acquisition and enhanced global data solutions, H1...
Qualigen Therapeutics to Present at LD Micro Main Event XV
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on...
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the LIBERTY® Robotic System
HINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated...
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
A Multicenter Open Label Study of QRX003 Topical Lotion in Netherton Syndrome Patients Who Are Currently Receiving Systemic Biologic Therapy.ASHBURN,...
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
Figure 1 SARS-COV-2 50% Tissue Culture Infectious Dose (TCID50) measurement in response to treatment with R327 in Syrian golden hamsters....
ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site
Immix Biopharma, Inc. (NASDAQ:IMMX) ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma...
Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)...
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigorWALTHAM, Mass., Oct. 18, 2022 (GLOBE...
SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting
BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent...
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid TumorsWILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude...
Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing...
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,...
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers...
LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
– LX1004 is an adeno-associated virus (AAV) based gene therapy for the treatment of CLN2 Batten disease – – In...